Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of HR20033 FDC vs Individual Components in Healthy Subjects
NCT05108350Phase 1Unknown
- Sponsor
- Shandong Suncadia Medicine Co., Ltd.
- Start
- Nov 2021
- Primary completion
- Dec 2021
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, open-label trial of henagliflozin in type 2 diabetes mellitus (T2DM) (4 cohorts), sponsored by Shandong Suncadia Medicine Co., Ltd. Primary endpoints: Maximum Plasma Concentration at Day 8, Area Under the Curve from time 0 to time t at Day 8 and 1 more. Status: unknown.
02
Drugs
henagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT05108350.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05108350.